The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

The health technology assessment agency has recommended that the drug be used on the NHS in England and Wales to treat adults with HER2-negative, locally advanced or metastatic breast cancer with ...

The higher dose regimen also reduced the risk ... metastatic non-small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease ...

sought to evaluate the prevalence of recurrence in patients with pheochromocytomas and sympathetic paragangliomas (PGLs; collectively referred to as PPGLs) and to identify predictors of recurrence ...

If lung cancer spreads to the brain, it would be called primary lung cancer metastatic ... as some of the risk factors for cancer, such as smoking, raise the risk of several types of cancer. There are ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

Diseases have well-defined causes like infections or genetic mutations. Tuberculosis is a disease caused by Mycobacterium tuberculosis, the bacterium. Disorders often have more than one cause and ...

Background Mpox emerged as a significant global public health concern during the 2022–2023 outbreak, impacting populations in ...

The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to the Vanderbilt University Medical Center study ...

A pathogenic gene mutation is a change in the DNA sequence of a gene that causes a person to have or be at risk of developing a certain genetic disorder or disease, such as cancer. Pathogenic ...

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.